Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
No sex gap found in tirzepatide heart outcomes. A new study of over 3,300 patients found no significant differences between men and women in major cardiovascular outcomes — including mortality, heart failure exacerbation, and MACE — when treated with tirzepatide for obesity and heart failure with preserved ejection fraction. Women did report more nausea and vomiting, though.
Tirzepatide levels the playing field — at least for the heart
A new retrospective study published in Therapeutic Advances in Cardiovascular Disease found that men and women with obesity and heart failure with preserved ejection fraction (HFpEF) experienced broadly similar cardiovascular outcomes when treated with tirzepatide. Researchers analyzed data from 3,308 propensity-matched patients across 110 healthcare organizations between June 2022 and January 2025.
While men had a modestly lower risk of all-cause hospitalization than women, the differences in mortality, heart failure exacerbation, major adverse cardiovascular events (MACE), and new-onset atrial fibrillation were not statistically significant. Women did experience significantly more nausea and vomiting — a known GI side effect of tirzepatide — but diarrhea rates were similar across sexes.
By the Numbers
Why it matters: HFpEF disproportionately affects women, and sex-based differences in treatment response are a known concern. These findings suggest tirzepatide may offer equitable cardiovascular benefits regardless of sex — an encouraging signal for a drug increasingly used in this high-risk population.
